目的 探討注射用黃芪多糖藥物血清在體外對(duì)耐順鉑（DDP）人肺腺癌A549/DDP細(xì)胞株的耐藥逆轉(zhuǎn)作用。方法 通過建立小鼠腫瘤模型，運(yùn)用血清藥理學(xué)方法，以人肺腺癌敏感細(xì)胞A549和耐藥細(xì)胞A549/DDP為研究對(duì)象，采用細(xì)胞毒實(shí)驗(yàn)（MTT）方法，探討注射用黃芪多糖對(duì)耐順鉑人肺腺癌細(xì)胞A549/DDP的耐藥逆轉(zhuǎn)作用。結(jié)果 注射用黃芪多糖藥物血清高、中、低劑量組分別與DDP合用時(shí)對(duì)A549/DDP細(xì)胞的耐藥逆轉(zhuǎn)倍數(shù)分別為1.24、1.41、1.34；且中、高劑量組與陽性對(duì)照DDP組比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。結(jié)論 注射用黃芪多糖能明顯增加A549/DDP耐藥細(xì)胞對(duì)DDP的敏感性，提高細(xì)胞死亡率，具有耐藥逆轉(zhuǎn)作用。

Objective To investigate the resistance reversal effect of the drug serum of astragalus polysaccharides for injection (API) in vitro on cisplatin-resistant human lung adenocarcinoma cell line A549/DDP. Methods The model of tumor-bearing mice was established, and using serum pharmacology method and taking human lung adenocarcinoma sensitive cell A549 and drug-resistant cell A549/DDP as the research objects, the resistance reversal effect of API on cisplatin-resistant human adenocarcinoma cells A549/DDP was studied in cell toxicity experiment by MTT method. Results The resistance reversal multiples of high-, mid-, and low-dose groups of API drug serum to A549/DDP cells were 1.24, 1.41, and 1.34, respectively; The data in mid- and high-dose groups had significant difference (P < 0.05) compared with DDP (positive control) group. Conclusion API could obviously increase the sensitivity of A549/DDP cells on DDP and improve the cell mortality. API has the resistance reversal effect.

天津市應(yīng)用基礎(chǔ)及前沿技術(shù)研究計(jì)劃（青年基金項(xiàng)目）（12JCQNJC07500）；天津市高等學(xué)校科技發(fā)展基金計(jì)劃項(xiàng)目（20110223）